Inhibrx Shares Slip Despite Positive Cancer Trial Results for INBRX-106
Inhibrx Shares Slip Despite Positive Cancer Trial Results for INBRX-106
Inhibrx Biosciences reported encouraging early Phase 2 data for its experimental cancer therapy INBRX-106, but the company’s stock still moved lower on Monday after an initial premarket jump.
The trial tested INBRX-106 together with pembrolizumab, widely known as Keytruda, in patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma. According to reported data, 11 of 25 patients receiving the combination therapy had a confirmed objective response, compared with 6 of 28 patients treated with pembrolizumab alone.
Promising Response Rate, But Investors Stay Cautious
The combination treatment produced a confirmed objective response rate of about 44%, while pembrolizumab alone showed about 21.4%. This suggests the experimental drug may improve treatment activity when added to an established immunotherapy.
Even so, Inhibrx shares slipped about 1% to around $133 after previously rising as much as 10% in premarket trading. The reaction shows that positive clinical data does not always lead to a higher stock price, especially when expectations are already very high.
Why the Stock Fell After Good News
One major reason may be that investors had already priced in strong results. Inhibrx shares had risen sharply over the past year, helped by optimism around its cancer-drug pipeline, including INBRX-106 and another therapy called ozekibart, also known as INBRX-109. Barron’s noted that the stock had surged roughly 1,000% over the previous year, setting a very high bar for new trial updates.
In biotech investing, even positive trial results can cause selling if traders expected even stronger data. Some investors may also have taken profits after the stock’s huge rally.
What INBRX-106 Is Designed to Do
INBRX-106 is an experimental cancer immunotherapy being studied for its ability to stimulate the immune system. It targets OX40, a protein involved in activating T cells, which are immune cells that can help fight cancer. Reuters previously reported that major pharmaceutical companies had shown interest in Inhibrx’s INBRX-106 program because of its potential connection to Keytruda-based treatment strategies.
Next Steps for Inhibrx
Inhibrx plans to begin a Phase 3 trial in the third quarter of 2026. The company also expects to provide more data on progression-free survival in the fourth quarter of 2026. These future updates will be important because investors and doctors will want to know whether the improved response rate leads to longer disease control.
Chief Executive Mark Lappe expressed optimism about the early data, but the company still needs larger and more mature trial results before INBRX-106 can move closer to possible regulatory approval.
Bigger Picture for the Biotech Sector
The Inhibrx update highlights both the promise and risk of biotech stocks. A small or mid-sized biotechnology company can rise quickly when its drug candidates show strong clinical potential. However, these stocks can also be volatile because their value often depends on trial results, regulatory decisions, and possible partnership or acquisition interest.
For patients with advanced head and neck cancer, the early results may be encouraging. For investors, the message is more complex: Inhibrx has delivered positive data, but expectations remain high, and the company still has several major clinical and regulatory steps ahead.
#Inhibrx #CancerResearch #BiotechStocks #ClinicalTrials #SlimScan #GrowthStocks #CANSLIM